| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,500 | 13,300 | 19.09. | |
| 11,300 | 12,800 | 18.09. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | Burning Rock Biotech Q3 non-GAAP EPS of RMB -$0.17, revenue of RMB $134.77M | 1 | Seeking Alpha | ||
| 10.09. | Burning Rock Biotech Limited Q1 Loss Rises | 4 | RTTNews | ||
| 10.09. | Burning Rock Biotech Limited: Burning Rock Reports Second Quarter 2026 Financial Results | 520 | GlobeNewswire (Europe) | GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next-generation sequencing... ► Artikel lesen | |
| 10.09. | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.07. | Burning Rock CEO purchases $618,218 in company shares | 1 | Investing.com | ||
| BURNING ROCK BIOTECH Aktie jetzt für 0€ handeln | |||||
| 02.07. | Burning Rock Biotech Limited: Burning Rock Announces Founder's Purchase of Its ADSs | 206 | GlobeNewswire (Europe) | GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 09.06. | Burning Rock Biotech reports Q1 results | 1 | Seeking Alpha | ||
| 09.06. | Burning Rock Biotech Limited: Burning Rock Reports First Quarter 2026 Financial Results | 490 | GlobeNewswire (Europe) | GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next-generation sequencing... ► Artikel lesen | |
| 09.06. | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.04. | Burning Rock Biotech Limited: Burning Rock Publishes 2025 Annual Report on Form 20-F | 2 | GlobeNewswire (USA) | ||
| 28.04. | Burning Rock Biotech Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 02.04. | Burning Rock CEO purchases $546,604 in company shares | 1 | Investing.com | ||
| 02.04. | Burning Rock Biotech Limited: Burning Rock Announces Founder's Purchase of Its ADSs | 203 | GlobeNewswire (Europe) | GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 12.03. | Burning Rock Biotech Limited: Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results | 433 | GlobeNewswire (Europe) | GUANGZHOU, China, March 12, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next-generation sequencing... ► Artikel lesen | |
| 05.01. | Burning Rock Biotech Limited: Burning Rock Announces Founder's Purchase of Its ADSs | 329 | GlobeNewswire (Europe) | GUANGZHOU, China, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 23.12.25 | Burning Rock Biotech Limited: Burning Rock Announces Results of 2025 Annual General Meeting | 329 | GlobeNewswire (Europe) | GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 20.11.25 | Burning Rock Biotech Limited: Burning Rock Reports Third Quarter 2025 Financial Results | 338 | GlobeNewswire (Europe) | GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | BioNTech SE: Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge | Gotistobart zeigte weiterhin Potenzial als chemotherapiefreie Monotherapie zur Reaktivierung der Anti-Tumor-Immunität in bereits vorbehandelten Patientinnen und Patienten mit Plattenepithelkarzinom... ► Artikel lesen | |
| MEDIGENE | 0,005 | -3,70 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| MODERNA | 134,16 | +0,12 % | Moderna und BioNTech lassen Corona endgültig hinter sich | Aus dem alten Duell der beiden Corona-Gewinner ist ein neuer Wettbewerb geworden. Moderna erlebt nach überzeugenden Phase-3-Daten für eine personalisierte Krebstherapie eine spektakuläre Neubewertung.... ► Artikel lesen | |
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 20.09. (10:36 Uhr): Meine aktuelle Lageeinschätzung | ||
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| CRISPR THERAPEUTICS | 49,155 | -0,17 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| REGENERON PHARMACEUTICALS | 685,10 | +0,53 % | Regeneron auf Morgan Stanley Konferenz: Wachstum stützt sich auf Dupixent | ||
| VIVOSIM LABS | 0,223 | -1,67 % | VivoSim Labs, Inc.: VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs | ||
| CLINUVEL | 5,022 | -1,26 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| GENMAB | 302,50 | +0,33 % | H.C. Wainwright reiterates Genmab stock rating at buy, $40 target | ||
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen |